SCHEMBL2117745

SCHEMBL2117745

COc1nccc(S(=O)(=O)Nc2cc(-c3ccns3)ccc2C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
MAPT P10636 7/20 0.39
KDM4E B2RXH2 5/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 2/20 0.36
HSP90AA1 P07900 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119403 0.85 ALDH1A1 (0.48) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2121542 0.82 ALDH1A1 (0.41) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2117520 0.82 MAPT (0.39) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2116757 0.81 MAPT (0.41) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2119284 0.80 TRIM24 (0.45) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2118052 0.80 GHSR (0.42) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2119339 0.80 ACLY (0.48) PIK3CAMTORACLY
SCHEMBL2119232 0.79 MAPT (0.45) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2119861 0.79 EDNRA (0.39) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL2117734 0.78 KIT (0.44) ALDH1A1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 ALDH1A1 1063/4885MAPT 4747/4885KDM4E 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.